Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review
Headache: The Journal of Head and Face Pain · 2025
DOI: 10.1111/head.14877 ↗At a glance
Übersichtsarbeit in Headache: The Journal of Head and Face Pain, 2025. Written by Richard B Lipton and 2 co-authors. Institution: Department of Neurology, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA. Major MEDLINE topics: Dihydroergotamine, Nausea, Migraine Disorders, Analgesics, Non-Narcotic. 43 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Satsuma Pharmaceuticals, Inc..
Abstract (original language)
Objective
To assess the relationships between dihydroergotamine (DHE) pharmacokinetic (PK) parameters, clinical efficacy, and nausea incidence to determine a DHE PK profile that optimizes efficacy while minimizing adverse events (AEs), particularly nausea.
Background
Dihydroergotamine is a widely used option for the acute treatment of migraine. Although multiple DHE dosage forms, with varying PK and AE profiles, have been evaluated in randomized controlled trials (RCTs), the relationships between PK profile, efficacy, and the common DHE‐related AE, nausea, have not been comprehensively evaluated.
Methods
A literature search identified RCTs evaluating the efficacy (2‐h pain relief [2hPR]) of different DHE dosage forms. The PK profiles for these DHE dosage forms were determined from published literature. Univariate regression analyses were performed to determine the PK parameters that best predicted 2hPR across DHE dosage forms. The relationship between maximum plasma concentration ( C max ) and nausea incidence for various dosage forms was determined from published Phase 1 trials.
Results
The literature search identified nine RCTs with DHE dosage forms that reported 2hPR: DHE liquid nasal spray (four studies), DHE administered subcutaneously (three), and DHE administered via oral pulmonary inhalation (two). The DHE PK parameters that best predicted 2hPR rates were C max and area under the curve from time zero to 0.5 h post‐dose (AUC 0‐0.5h ) ( R 2 = 0.59 for each). Across Phase 1 trials, nausea incidence was minimal when C max was
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA.
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, New York, USA.
- Satsuma Pharmaceuticals, Inc., Durham, North Carolina, USA.
ORCID profiles: Detlef Albrecht
Funding
- Satsuma Pharmaceuticals, Inc.
Cite
APA
Lipton, R. B., Kollins, J. A., & Albrecht, D. (2025). Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14877
Vancouver
Lipton RB, Kollins JA, Albrecht D. Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14877
BibTeX
@article{Lipton2025,
author = {Lipton, Richard B and Kollins, John A and Albrecht, Detlef},
title = {Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea—A narrative review},
journal = {Headache: The Journal of Head and Face Pain},
year = {2025},
doi = {10.1111/head.14877}
}
EUVIMED